Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market

Author's Avatar
Oct 03, 2020
Article's Main Image

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.